Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker

Saqib Raza Khan, Matthias Scheffler, Salman Muhammad Soomar, Yasmin Abdul Rashid, Munira Moosajee, Aamir Ahmad, Afsheen Raza, Shahab Uddin

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Lung cancer is one of the most common solid malignancies. Tissue biopsy is the standard method for accurately diagnosing lung and many other malignancies over decades. However, molecular profiling of tumors leads to establishing a new horizon in the field of precision medicine, which has now entered the mainstream in clinical practice. In this context, a minimally invasive complementary method has been proposed as a liquid biopsy (LB) which is a blood-based test that is gaining popularity as it provides the opportunity to test genotypes in a unique, less invasive manner. Circulating tumor cells (CTC) captivating the Circulating-tumor DNA (Ct-DNA) are often present in the blood of lung cancer patients and are the fundamental concept behind LB. There are multiple clinical uses of Ct-DNA, including its role in prognostic and therapeutic purposes. The treatment of lung cancer has drastically evolved over time. Therefore, this review article mainly focuses on the current literature on circulating tumor DNA and its clinical implications and future goals in non-small cell lung cancer.

Original languageEnglish
Article number154455
JournalPathology Research and Practice
Publication statusPublished - May 2023


  • Biomarker
  • CtDNA
  • Lung cancer
  • Precision medicine
  • Treatment


Dive into the research topics of 'Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker'. Together they form a unique fingerprint.

Cite this